γ-氨基丁酸能药物对糖尿病视网膜病变影响的大规模美国人群队列评估
基于美国TriNetX多机构电子健康记录的回溯性队列研究,纳入成人2型糖尿病且有眼科随访者,比较有GABA能药物处方(6个月至5年)与从未处方者的糖尿病视网膜病变(DR)结局。经倾向评分匹配后,各暴露时长均与DR发生风险显著降低相关,短期暴露亦与DR进展和并发症风险降低相关。
要点
- 6个月至5年GABA能药物暴露均与DR发生风险显著降低相关。
- 基线轻中度非增殖期DR患者中,6个月和1年暴露与进展风险降低相关。
- 6个月至3年暴露与DR并发症风险显著降低相关。
核心结论
- GABA能药物使用,尤其是短期暴露,与DR发生、进展和并发症风险降低相关。
- 这些探索性发现支持GABA能调节在糖尿病视网膜疾病中的潜在作用。
研究设计与样本
- 回顾性临床队列研究,使用美国TriNetX协作网络的多机构电子健康记录数据。
- 研究对象为年龄≥18岁、患有2型糖尿病且有眼科随访的成人。
- 研究队列有6个月、1年、3年或5年的GABA能药物处方记录,对照队列从未有GABA能药物处方。
- 采用倾向评分匹配(PSM)平衡人口学、系统性合并症、GABA能药物常见适应症和眼科混杂因素。
主要发现
- PSM后,6个月、1年、3年、5年暴露组分别有110 495、99 187、63 194、40 810例无DR患者,对照组109 603例无DR患者。
- 与对照组相比,研究组6个月暴露的DR发生HR为0.61(95%CI 0.57-0.65),5年暴露的HR为0.81(95%CI 0.77-0.85)。
- 基线轻中度非增殖期DR患者(n=14 644)中,6个月暴露进展至重度非增殖期DR、增殖期DR或需干预的HR为0.75(95%CI 0.68-0.82),1年暴露HR为0.69(95%CI 0.73-0.86)。
- 6个月暴露的DR并发症HR为0.74(95%CI 0.68-0.80),3年暴露HR为0.80(95%CI 0.84-0.86)。
- 按4种特定药物适应症分层,6个月处方时长均 consistently 显示DR发生风险降低。
关键数值与推荐
- 主要结局指标为风险比(HR)和95%置信区间(CI),显著性阈值为<0.9或>1.1。
- DR发生风险在6个月至5年各时间点均显著降低。
- DR进展风险在6个月和1年暴露时显著降低。
- DR并发症风险在6个月至3年暴露时显著降低。
临床怎么用
- GABA能药物暴露与DR发生、进展和并发症风险降低相关,提示其潜在保护作用。
- 短期暴露(如6个月)即与风险降低相关,但需进一步研究确认因果性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate how exposure to GABAergic medications affects diabetic retinopathy (DR) development, progression, and complications. DESIGN: Retrospective clinical cohort study using multi-institutional electronic health record data (TriNetX, US Collaborative Network). PARTICIPANTS: Adults aged ≥ 18 years with type 2 diabetes mellitus with ophthalmology follow-up. Study cohorts had GABAergic prescription records for 6-months, 1-year, 3-years, or 5-years; control cohorts had no GABAergic prescriptions ever. METHODS: Cohorts were propensity-score matched (PSM) on demographics, systemic comorbidities, common indications for GABAergic medications, and ophthalmic confounders. Outcomes included incident DR, progression from mild/moderate nonproliferative DR to severe nonproliferative DR, proliferative DR, or interventions required in advanced DR, and incident DR complications. MAIN OUTCOME MEASURES: Hazard ratio (HR) and 95% confidence intervals (CI); significance threshold < 0.9 or > 1.1. RESULTS: After successful PSM, there were 110 495 (6-months), 99 187 (1-year), 63 194 (3-years), and 40 810 (5-years) DR-naive study patients with the respective GABAergic prescription durations of interest. Compared to 109 603 DR-naive control patients, study patients demonstrated a significantly reduced HR for DR development at all time points from 6-months (HR 0.61, 95% CI 0.57-0.65) to 5-years (HR 0.81, 95% CI 0.77-0.85). Study patients (n = 14 644) with baseline mild/moderate nonproliferative DR had a significantly reduced hazard of progressing to severe nonproliferative DR, proliferative DR, or DR interventions with 6-months (HR 0.75, 95% CI 0.68-0.82) and 1-year (HR 0.69, 95% CI 0.73, 0.86) GABAergic exposure. Prescription for 6-months (HR 0.74, 95% CI 0.68-0.80) to 3-years (HR 0.80, 95% CI 0.84-0.86) was associated with a significantly reduced hazard for DR complications. Stratification by 4 specific medication indications consistently showed a reduced hazard for DR development with a 6-month prescription duration. CONCLUSIONS: GABAergic medication use, particularly short-term exposure, is associated with a reduced hazard of DR development, progression, and complications. These exploratory findings support a potential role of GABAergic modulation in diabetic retinal disease.
引用
- Kim SB, Zhou MY, Allan KC, et al. Evaluation of the Impact of Gamma-Aminobutyric Acid on Diabetic Retinopathy in a Large US Population-Based Cohort. Am J Ophthalmol. 2026. PMID: 42435831. doi:10.1016/j.ajo.2026.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。